Monitoring of Antiplatelet Therapy

Platelets

Volumn , Issue , 2013, Pages 603-633

  Gurbel, Paul A ^a   Tantry, Udaya S ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882582778     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00030-4     Document Type: Chapter

References (218)

1. Becker R.C., Meade T.W., Berger P.B., et al. Chest 2008, 133:776S-814S. American College of Chest Physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
2. Gurbel P.A., Tantry U.S. Combination antithrombotic therapies. Circulation 2010, 121:569-583.
3. Dorsam R.T., Kunapuli S.P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004, 113:340-345.
4. Mahaffey K.W., Wojdyla D.M., Carroll K., et al. Ticagrelor compared with Clopidogrel by Geographic Region in the Platelet inhibition and patient outcomes (PLATO) Trial. Circulation 2011, 124:544-554.
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
6. Mehta S.R., Tanguay J.F., Eikelboom J.W., et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010, 376:1233-1243.
7. Craven L.L. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg 1950, 4:95.
8. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971, 231:232-235.
9. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-60.
10. Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995, 11:221-227.
11. Weber A.A., Przytulski B., Schanz A., et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002, 13:37-40.
12. Hass W.K., Easton J.D., Adams H.P., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321:501-507.
13. Bertrand M.E., Rupprecht H.J., Urban P., Gershlick A.H. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation 2000, 102:624-629.
14. Hollopeter G., Jantzen H.M., Vincent D., Li G., England L., Ramakrishnan V., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409:202-207.
15. Helton T.J., Bavry A.A., Kumbhani D.J., et al. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am J Cardiovasc Drugs 2007, 7:289-297.
16. Gurbel P.A., Bliden K.P., Hayes K.M., Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004, 2:535-545.
17. Herbert J.M., Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003, 3:113-122.
18. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
19. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
20. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007, 50:1822-1834.
21. Gurbel P.A., Bliden K.P., Hayes K.M., Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther 2004, 2:535-545.
22. Trip M.D., Cats V.M., van Capelle F.J., Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990, 322:1549-1554.
23. Hirsh J. Hyperactive platelets and complications of coronary artery disease. N Engl J Med 1987, 316:1543-1544.
24. 2 synthase. Nat Struct Biol 1995, 2:637-643.
25. Chiang N., Serhan C.N. Aspirin triggers formation of anti-inflammatory mediators: new mechanism for an old drug. Discov Med 2004, 4:470-475.
26. Di Nino G., Silver M.J., Murphy S. Monitoring the entry of new platelets into circulation after ingestion of aspirin. Blood 1983, 61:1081.
27. Reilly I.A., FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987, 69:180-186.
28. Patrignani P. Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003, 110:281-286.
29. Rocca B., Secchiero P., Ciabattoni G., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002, 99:7634-7639.
30. Zimmermann N., Wenk A., Kim U., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003, 108:542-547.
31. Hanson S.R., Harker L.A., Bjornsson T.D. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. J Clin Invest 1985, 75:1591-1599.
32. Gaspari F., Viganò G., Orisio S., et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987, 79:1788-1797.
33. van Genderen P.J., van Vliet H.H., Prins F.J., et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol 1997, 75:215-220.
34. Ratnatunga C.P., Edmondson S.F., Rees G.M., et al. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992, 85:1077-1082.
35. Undas A., Brummel-Ziedins K.E., Mann K.G. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007, 109:2285-2292.
36. Szczeklik A., Musial J., Undas A., et al. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996, 16:948-954.
37. Bjornsson T.D., Schneider D.E., Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J Pharmacol Exp Ther 1989, 250:154-161.
38. Michelson A.D., Cattaneo M., Eikelboom J.W., Gurbel P., Kottke-Marchant K., Kunicki T.J., et al. Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005, 3:1309-1311.
39. Tantry U.S., Mahla E., Gurbel P.A. Aspirin resistance. Prog Cardiovasc Dis 2009, 52:141-152.
40. Haubelt H., Anders C., Vogt A., Hoerdt P., Seyfert U.T., Hellstern P. Variables influencing platelet function analyzer-100 closure times in healthy individuals. Br J Haematol 2005, 130:759-767.
41. Hovens M.M., Snoep J.D., Eikenboom J.C., et al. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153:175-181.
42. Hurlen M., Seljeflot I., Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1998, 32:233-237.
43. Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically. Can J Cardiol 1995, 11:221-227.
44. Buchanan M.R., Schwartz L., Bourassa M., et al. Results of the BRAT study-a pilot study investigating the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000, 16:1385-1390.
45. Grotemeyer K.H., Scharafinski H.W., Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397-403.
46. Gum P.A., Kottke-Marchant K., Welsh P.A., et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
47. Gum P.A., Kottke-Marchant K., Poggio E.D., Sapp S.K., Topol E.J., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88:230-235.
48. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650-1655.
49. Eikelboom J.W., Hankey G.J., Thom J., et al. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation 2008, 118:1705-1712.
50. Wang J.C., Aucoin-Barry D., Manuelian D., et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003, 92:1492-1494.
51. Chen W.H., Lee P.Y., Ng W., et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004, 43:1122-1126.
52. Gonzalez-Conejero R., Rivera J., Corral J, et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. Stroke 2005, 36:276-280.
53. Tantry U.S., Bliden K.P., Gurbel P.A. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J Am Coll Cardiol 2005, 46:1705-1709.
54. Schwartz K.A., Schwartz D.E., Ghosheh K., et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973-975.
55. Gurbel P.A., Bliden K.P., DiChiara J., et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007, 115:3156-3164.
56. Lordkipanidze M., Pharand C., Schampaert E., et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007, 28:1702-1708.
57. Faraday N., Becker D.M., Yanek L.R., et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006, 98:774-779.
58. Frelinger A.L., Furman M.I., Linden M.D., et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113:2888-2896.
59. Chen W.H., Cheng X., Lee P.Y., et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007, 120:631-635.
60. Lev E.I., Patel R.T., Maresh K.J., et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006, 47:27-33.
61. Marcucci R., Paniccia R., Antonucci E., et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006, 98:1156-1159.
62. Gianetti J., Parri M.S., Sbrana S., et al. Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study. Thromb Res 2006, 118:487-493.
63. Foussas S.G., Zairis M.N., Patsourakos N.G., et al. The impact of oral antiplatelet responsiveness on the long-term prognosis after coronary stenting. Am Heart J 2007, 154:676-681.
64. Malek L.A., Spiewak M., Filipiak K.J., et al. Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes. Kardiol Pol 2007, 65:40-45.
65. Borna C., Lazarowski E., van Heusden C., et al. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005, 3:10.
66. DiChiara J., Bliden K.P., Tantry U.S., et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the Aspirin-Induced Platelet Effect (ASPECT) study. Diabetes 2007, 56:3014-3019.
67. Jilma B., Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol 2001, 88:1348-1349.
68. Ault K.A., Rinder H.M., Mitchell J., Carmody M.B., Vary C.P., Hillman R.S. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992, 98:637-646.
69. Grove E.L., Hvas A.M., Mortensen S.B., Larsen S.B., Kristensen S.D. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 2011, 9:185-191.
70. Addad F., Chakroun T., Elalamy I., Abderazek F., Chouchene S., Dridi Z., et al. Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. Int J Hematol 2010, 92:296-301.
71. Capodanno D., Patel A., Dharmashankar K., Ferreiro J.L., Ueno M., Kodali M., et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 2011, 4:180-187.
72. Bliden K.P., Tantry U.S., DiChiara J., Gurbel P.A. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. Circ Cardiovasc Interv 2011, 4:118-120.
73. Ohmori T., Yatomi Y., Nonaka T., et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006, 4:1271-1278.
74. Faraday N., Yanek L.R., Mathias R., et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007, 115:2490-2496.
75. Lordkipanidzé M., Pharand C., Palisaitis D.A., et al. Aspirin resistance: truth or dare. Pharmacol Ther 2006, 112:733-743.
76. Farndale R.W., Hargreaves P.G., Dietrich J.L., et al. Measurement of platelet arachidonic acid metabolism. Methods Mol Biol 2004, 272:121-133.
77. Dobaczewski M., Golański J., Kowalski T., et al. Can we use adenosine diphosphate (ADP) to study "aspirin resistance"? The Janus faces of ADP-triggered platelet aggregation. Pharmacol Rep 2008, 60:361-368.
78. Pulcinelli F.M., Pignatelli P., Celestini A., et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004, 43:979-984.
79. Santilli F., Rocca B., De Cristofaro R., et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". J Am Coll Cardiol 2009, 53:667-677.
80. Perneby C., Wallén N.H., Rooney C., et al. Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 2006, 95:652-658.
81. Harrison P., Segal H., Silver L., et al. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 2008, 19:119-124.
82. Mueller M.R., Salat A., Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997, 78:1003-1007.
83. Snoep J.D., Hovens M.M., Eikenboom J.C., et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007, 167:1593-1599.
84. Crescente M., Di Castelnuovo A., Iacoviello L., et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008, 99:14-26.
85. Reny J.L., De Moerloose P., Dauzat M., et al. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008, 6:444-450.
86. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Harmsze A.M., Hackeng C.M., et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 2011, 97:983-990.
87. Dichiara J., Bliden K.P., Tantry U.S., et al. Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets 2007, 18:414-423.
88. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
89. Kurth T., Glynn R.J., Walker A.M., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 2003, 108:1191-1195.
90. Hennekens C.H., Schneider W.R., Hebert P.R., Tantry U.S., Gurbel P.A. Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance.". Am Heart J 2010, 159:744-748.
91. Lev E.I., Ramabadran R.S., Guthikonda S., et al. Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol 2007, 99:124-128.
92. Goodman T., Ferro A., Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 2008, 66:222-232.
93. Kuliczkowski W., Witkowski A., Polonski L., et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on Antiplatelet Drugs Resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009, 30:426-435.
94. Hagihara K., Kazui M., Kurihara A., Yoshiike M., Honda K., Okazaki O., et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009, 37:2145-2152.
95. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N.A., Okazaki O., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010, 38:92-99.
96. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002, 30:1288-1295.
97. 12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 2006, 103:11069-11074.
98. Price M.J., Coleman J.L., Steinhubl S.R., Wong G.B., Cannon C.P., Teirstein P.S. Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006, 98:681-684.
99. Gurbel P.A., Bliden K.P., Butler K., Tantry U.S., Gesheff T., Wei C., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009, 120:2577-2585.
100. Bonello L., Tantry U.S., Marcucci R., et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933.
101. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360:363-75.
102. Gurbel P.A., Antonino M.J., Tantry U.S. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 2009, 5:989-1004.
103. Marín F., González-Conejero R., Capranzano P., Bass T.A., Roldán V., Angiolillo D.J. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 2009, 54:1041-1057.
104. Lau W.C., Gurbel P.A., Watkins P.B., Neer C.J., Hopp A.S., Carville D.G., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109:166-171.
105. Lau W.C., Welch T.D., Shields T., et al. The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011, 57:86-93.
106. Bliden K.P., DiChiara J., Lookman L., Singla A., Antonino M.J., Baker B.A., et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008, 52:531-533.
107. Berger J.S., Bhatt D.L., Steinhubl S.R., Shao M., Steg P.G., Montalescot G., et al. CHARISMA Investigators. Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation 2009, 120:2337-2344.
108. Desai N.R., Mega J.L., Jiang S., Cannon C.P., Sabatine M.S. Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009, 53:1273-1278.
109. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51:256-260.
110. Small D.S., Farid N.A., Payne C.D., Weerakkody G.J., Li Y.G., Brandt J.T., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008, 48:475-484.
111. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157:148.
112. Sibbing D., Morath T., Stegherr J., Braun S., Vogt W., Hadamitzky M., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009, 10:714-719.
113. Ferreiro J.L., Ueno M., Capodanno D., et al. Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. Circ Cardiovasc Interv 2010, 3:436-441.
114. Angiolillo D.J., Gibson C.M., Cheng S., et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 2011, 89:65-74.
115. Gurbel P.A., Bliden K.P., Fort J., Zhang Y., Plachetka J.R., Antonino M., et al. Pharmacodynamic Evaluation of Clopidogrel Plus PA32540: The Spaced PA32540 with Clopidogrel INteraction Gauging (SPACING) Study. Clin Pharmac Ther 2011, 90:860-866.
116. Verstuyft C., Simon T., Kim R.B. Personalized medicine and antiplatelet therapy: ready for prime time?. Eur Heart J 2009, 30:1943-1963.
117. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Jimenez-Quevedo P., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
118. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Barrera Ramírez C., Sabaté M., Fernandez C., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. J Invasive Cardiol 2004, 16:169-174.
119. Sibbing D., von Beckerath O., Schömig A., Kastrati A., von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis 2007, 18:335-339.
120. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C19 allele nomenclature. Available at: <>. [accessed July 2011]. http://www.cypalleles.ki.se/cyp2c19.htm.
121. Scott S.A., Sangkuhl K., Gardner E.E., et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clin Pharmacol Ther 2011, 90:328-332.
122. Gurbel P.A., Shuldiner A.R., Bliden K.P., et al. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. Am Heart J 2011, 161:598-604.
123. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-857.
124. Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest C.S., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007, 5:2429-2436.
125. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
126. Mega J.L., Simon T., Collet J.P., Anderson J.L., et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010, 304:1821-1830.
127. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Méneveau N., et al. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
128. Pare G., Mehta S.R., Yusuf S., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med 2010, 363:1704-1714.
129. Wallentin L., James S., Storey R.F., Armstrong M., Barratt B.J., Horrow J., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the Plato trial. Lancet 2010, 376:1320-1328.
130. Price M.J., Tantry U.S., Gurbel P.A. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Rev Cardiovasc Med 2011, 12:1-12.
131. Bouman H.J., Schömig E., van Werkum J.W., Velder J., Hackeng C.M., Hirschhäuser C., et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011, 17:110-116.
132. Price MJ, Murray SS, Angiolillo DJ, et al. GIFT Investigators. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 2012;59:1928-37.
133. Sibbing D., Koch W., Massberg S., et al. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011, 32:1605-1613.
134. Trenk D., Hochholzer W., Fromm M.F., et al. Paraoxonase-1 Q192R Polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011, 4:429-436.
135. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at: <>; [accessed 28.04.11]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/ucm203888.htm.
136. Jeong Y.H., Kim I.S., Park Y., Kang M.K., Koh J.S., Hwang S.J., et al. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study. JACC Cardiovasc Interv 2010, 3:731-741.
137. Gladding P., Webster M., Zeng I., Farrell H., Stewart J., Ruygrok P., et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 2008, 1:620-627.
138. Varenhorst C., James S., Erlinge D., Brandt J.T., Braun O.O., Man M., et al. Genetic variation of CYP2c19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J 2009, 30:1744-1752.
139. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009, 119:2553-2560.
140. Tantry U.S., Bliden K.P., Wei C., Storey R.F., Armstrong M., Butler K., et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010, 3:556-566.
141. Bhatt DL, Simonsen KL, Emison ES, et al., on behalf of the CHARISMA Executive Committee and Investigators. CHARISMA genomics. Paper presented at: Transcatheter Cardiovascular Therapeutics 2009 Meeting; September 30, 2009; San Francisco, California.
142. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
143. 12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011, 106:219-226.
144. Michelson A.D., Linden M.D., Furman M.I., et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance.'. J Thromb Haemost 2007, 5:75-81.
145. Price M.J., Berger P.B., Teirstein P.S., et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
146. Campo G., Parrinello G., Ferraresi P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011, 57:2474-2483.
147. Järemo P., Lindahl T.L., Fransson S.G., Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002, 252:233-238.
148. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007, 49:657-666.
149. Gurbel P.A., Bliden K.P., Guyer K., Cho P.W., Zaman K.A., Kreutz R.P., et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005, 46:1820-1826.
150. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85-92.
151. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003, 59:295-302.
152. Sibbing D., Braun S., Morath T., Mehilli J., Vogt W., Schömig A., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53:849-856.
153. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
154. Gurbel P.A., Bliden K.P., Zaman K.A., et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005, 111:1153-1159.
155. Gurbel P.A., Bliden K.P., Saucedo J.F., et al. Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indices and their relation to periprocedural infarction: results of the CLEAR PLATELETS-2 study. J Am Coll Cardiol 2009, 53:648-657.
156. Blindt R., Stellbrink K., de Taeye A., Müller R., Kiefer P., Yagmur E., et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007, 98:1329-1334.
157. Cuisset T., Frere C., Quilici J., et al. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. Thromb Haemost 2007, 97:282-287.
158. Frere C., Cuisset T., Quilici J., Camoin L., Carvajal J., Morange P.E., et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007, 98:838-843.
159. Geisler T., Langer H., Wydymus M., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27:2420-2425.
160. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K., et al. The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score. J Thromb Haemost 2008, 6:54-61.
161. Hochholzer W., Trenk D., Bestehorn H.P., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48:1742-1750.
162. Price M.J., Endemann S., Gollapudi R.R., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
163. Gurbel P.A., Antonino M.J., Bliden K.P., et al. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008, 19:595-604.
164. Gurbel P.A., Bliden K.P., Samara W., et al. The Clopidogrel Resistance and Stent Thrombosis (CREST) study. J Am Coll Cardiol 2005, 46:1827-1832.
165. Buonamici P., Marcucci R., Miglironi A., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
166. Bonello L., Paganelli F., Arpin-Bornet M., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
167. Cuisset T., Hamilos M., Sarma J., et al. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008, 101:1700-1703.
168. Migliorini A., Valenti R., Marcucci R., Parodi G., Giuliani G., Buonamici P., et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009, 120:2214-2221.
169. Marcucci R., Gori A.M., Paniccia R., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-342.
170. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52:1128-1133.
171. Cuisset T., Frere C., Quilici J., et al. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009, 104:1078-1082.
172. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
173. Samara W.M., Bliden K.P., Tantry U.S., Gurbel P.A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005, 115:89-94.
174. Tantry U.S., Bliden K.P., Gurbel P.A. What is the best measure of thrombotic risks-pretreatment platelet aggregation, clopidogrel responsiveness, or posttreatment platelet aggregation?. Catheter Cardiovasc Interv 2005, 66:597-598.
175. Price M.J., Berger P.B., Teirstein P.S., et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
176. Yusuf S., Zhao F., Mehta S.R., et al. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
177. Sibbing D., Schulz S., Braun S., et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010, 8:250-256.
178. Gurbel P.A., Bliden K.P., Navickas I.A., et al. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010, 160:346-354.
179. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51:1404-1411.
180. Bonello L., Camoin-Jau L., Armero S., Com O., Arques S., Burignat-Bonello C., et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009, 103:5-10.
181. Valgimigli M., Campo G., de Cesare N., Meliga E., et al. Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R) investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind prospective randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 2009, 119:3215-3222.
182. Cuisset T., Frere C., Quilici J., Morange P.E., Mouret J.P., Bali L., et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008, 1:649-653.
183. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115:708-716.
184. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75mg of clopidogrel for 30 days. Eur Heart J 2007, 28:1814-1819.
185. Angiolillo D.J., Costa M.A., Shoemaker S.B., Desai B., Bernardo E., Suzuki Y., et al. Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am J Cardiol 2008, 101:440-445.
186. Matetzky S., Fefer P., Shenkman B., Varon D., Savion N., Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol 2008, 102:524-529.
187. Aleil B., Jacquemin L., De Poli F., Zaehringer M., Collet J.P., Montalescot G., et al. Clopidogrel 150mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv 2008, 1:631-638.
188. Jeong Y.H., Lee S.W., Choi B.R., Kim I.S., Seo M.K., Kwak C.H., et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009, 53:1101-1109.
189. Gurbel P.A., Bliden K.P., Antonino M.J., Stephens G., Gretler D.D., Jurek M.M., et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients. J Thromb Haemost 2010, 8:43-53.
190. Gurbel P.A., Bliden K.P., Butler K., Antonino M.J., Wei C., Teng R., et al. REsponse to Ticagrelor in Clopidogrel Non-responders and ReSPONDers and the Effect of Switching Therapies: the RESPOND Study. Circulation 2010, 121:1188-1199.
191. Gurbel P.A., Tantry U.S. An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial. JAMA 2011, 305:1136-1137.
192. Kushner F.G., et al. Focused Updates: ACC/AHA Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120:2271-2306.
193. Wright R.S., Anderson J.L., Adams C.D., Bridges C.R., Casey D.E., Ettinger S.M., et al. ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:2022-2060.
194. Ferraris V.A., Brown J.R., Despotis G.J., Hammon J.W., Reece T.B., Saha S.P., et al. update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011, 91:944-982.
195. Brilinta, FDA, drug insert.
196. Reece M.J., Klein A.A., Salviz E.A., Hastings A., Ashworth A., Freeman C., et al. Near-patient platelet function testing in patients undergoing coronary artery surgery: a pilot study. Anaesthesia 2011, 66:97-103.
197. Rinder C.S., Bohnert J., Rinder H.M., Mitchell J., Ault K., Hillman R. Platelet activation and aggregation during cardiopulmonary bypass. Anesthesiology 1991, 75:388-393.
198. Kwak Y.L., et al. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol 2010, 56:1994-2002.
199. Nuttall G.A., et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001, 94:773-781.
200. Shore-Lesserson L., et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999, 88:312-319.
201. Wasowicz M., McCluskey S.A., Wijeysundera D.N., Yau T.M., Meinri M., Beattie W.S., et al. The incremental value of thrombelastography for prediction of excessive blood loss after cardiac surgery: an observational study. Anesth Analg 2010, 111:331-338.
202. Chen L., et al. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004, 128:425-431.
203. Mahla E, Suarez TA, Bliden KP, et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv 2012;5:261-9.
204. Tantry U.S., Gurbel P.A. Assessment of oral antithrombotic therapy by platelet function testing. Nat Rev Cardiol 2011, 8(10):572-579.
205. Chin C.T., Roe M.T., Fox K.A., Prabhakaran D., et al. TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010, 160:16-22. e1.
206. Abraham N.S., Hlatky M.A., Antman E.M., et al. ACCF/ACG/AHA. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010, 122:2619-2633.
207. Tantry U.S., Kereiakes D.J., Gurbel P.A. Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. JACC Cardiovasc Interv 2011, 4:365-380.
208. U.S. Food and Drug Administration. Information for Healthcare Professionals: Update to the Labeling of Clopidogrel Bisulfate (Marketed as Plavix) to Alert Healthcare Professionals About a Drug Interaction With Omeprazole (Marketed as Prilosec and Prilosec OTC) [online alert] November 17, 2009. Available at: <>; [accessed 10.08.11]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm190 787.htm.
209. European Medicines Agency. Public Statement on Possible Interaction Between Clopidogrel and Proton-Pump Inhibitors [online alert] May 29, 2009. Available at: <>; [accessed 10.08.11]. http://www.ema.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf.
210. Steinhubl S.R., Talley J.D., Braden G.A., et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001, 103:2572-2578.
211. Gurbel P.A., Bliden K.P., Tantry U.S. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006, 48:2186-2191.
212. Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:2022-60.
213. Ferraris V.A., Brown J.R., Despotis G.J., Hammon J.W., Reece T.B., Saha S.P., et al. update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011, 91:944-982.
214. Kohl P., et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010, 31:2501-2555.
215. Wright R.S., Anderson J.L., Adams C.D., et al. ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:2022-2060.
216. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
217. Levine G.N., Bates E.R., Blankenship J.C., et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124:e574-e651.
218. Ferraris V.A., Brown J.R., Despotis G.J., et al. Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011, 91:944-982.